Effects of Fenformin On Cell Viability and FGFR2 Expression in PC-3 Human Prostate Cancer Cell Line

Dilan Çetinavcı; Melike Özgül Önal; Gürkan Yiğittürk; Hülya Elbe; Feral Öztürk

Makale detayları

Effects of Fenformin On Cell Viability and FGFR2 Expression in PC-3 Human Prostate Cancer Cell Line

Yazarlar:

Dilan Çetinavcı | Melike Özgül Önal | Gürkan Yiğittürk | Hülya Elbe | Feral Öztürk

Yayıncı:

Mugla Sitki Kocman University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.10 Issue 2, pp.84-89

Belge Tipi:

Makale

Yayın Tarihi:

8/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001296749

pISSN:

2148-8118

Anahtar kelimeler:

Özet:

 Prostate cancer is the second most common cause of cancer-related death in men. New drugs are needed to treat prostate cancer due to the development of resistance to chemotherapeutics. Although phenformin is a biguanide antidiabetic drug, it also has anticarcinogenic effects. Fibroblast growth factor receptor 2 FGFR2 is a membrane receptor that promotes cell proliferation and differentiation. Our study; was aimed to investigate the effects of phenformin on FGFR2 in PC-3 human prostate cancer cells. Experimental groups; control groups were administered 1 mM, 2 mM, 5 mM, and 10 mM phenformin. WST-1 cell viability analysis was performed 24 hours after phenformin administration, and H-Score was calculated after immunocytochemical staining for FGFR2. The SPSS program was used for statistical analysis. According to the WST-1 analysis; when the control group and the 5 mM phenformin group, the control group with the 10 mM phenformin group, and the 1 mM phenformin group with the 10 mM phenformin group were compared, a statistically significant decrease in cell viability was detected p0.05, for all. According to the H-Score results; The decrease in FGFR2 expression between control group and 5 mM phenformin group, control group and 10 mM phenformin group, 1 mM phenformin group and 5 mM phenformin group, and 1 mM phenformin group and 10 mM phenformin group was statistically significant p0.05, for all. Our study showed that phenformin has dose dependent effect in reducing FGFR2 expression from PC-3 human prostate cancer cells and inhibiting cell proliferation, and 10 mM phenformin was the most effective dose.

 Prostate cancer is the second most common cause of cancer-related death in men. New drugs are needed to treat prostate cancer due to the development of resistance to chemotherapeutics. Although phenformin is a biguanide antidiabetic drug, it also has anticarcinogenic effects. Fibroblast growth factor receptor 2 FGFR2 is a membrane receptor that promotes cell proliferation and differentiation. Our study; was aimed to investigate the effects of phenformin on FGFR2 in PC-3 human prostate cancer cells. Experimental groups; control groups were administered 1 mM, 2 mM, 5 mM, and 10 mM phenformin. WST-1 cell viability analysis was performed 24 hours after phenformin administration, and H-Score was calculated after immunocytochemical staining for FGFR2. The SPSS program was used for statistical analysis. According to the WST-1 analysis; when the control group and the 5 mM phenformin group, the control group with the 10 mM phenformin group, and the 1 mM phenformin group with the 10 mM phenformin group were compared, a statistically significant decrease in cell viability was detected p0.05, for all. According to the H-Score results; The decrease in FGFR2 expression between control group and 5 mM phenformin group, control group and 10 mM phenformin group, 1 mM phenformin group and 5 mM phenformin group, and 1 mM phenformin group and 10 mM phenformin group was statistically significant p0.05, for all. Our study showed that phenformin has dose dependent effect in reducing FGFR2 expression from PC-3 human prostate cancer cells and inhibiting cell proliferation, and 10 mM phenformin was the most effective dose.

 Prostate cancer is the second most common cause of cancer-related death in men. New drugs are needed to treat prostate cancer due to the development of resistance to chemotherapeutics. Although phenformin is a biguanide antidiabetic drug, it also has anticarcinogenic effects. Fibroblast growth factor receptor 2 FGFR2 is a membrane receptor that promotes cell proliferation and differentiation. Our study; was aimed to investigate the effects of phenformin on FGFR2 in PC-3 human prostate cancer cells. Experimental groups; control groups were administered 1 mM, 2 mM, 5 mM, and 10 mM phenformin. WST-1 cell viability analysis was performed 24 hours after phenformin administration, and H-Score was calculated after immunocytochemical staining for FGFR2. The SPSS program was used for statistical analysis. According to the WST-1 analysis; when the control group and the 5 mM phenformin group, the control group with the 10 mM phenformin group, and the 1 mM phenformin group with the 10 mM phenformin group were compared, a statistically significant decrease in cell viability was detected p0.05, for all. According to the H-Score results; The decrease in FGFR2 expression between control group and 5 mM phenformin group, control group and 10 mM phenformin group, 1 mM phenformin group and 5 mM phenformin group, and 1 mM phenformin group and 10 mM phenformin group was statistically significant p0.05, for all. Our study showed that phenformin has dose dependent effect in reducing FGFR2 expression from PC-3 human prostate cancer cells and inhibiting cell proliferation, and 10 mM phenformin was the most effective dose.

 Prostat kanseri, erkeklerde kansere bağlı ölümlerin ikinci en sık nedenidir. Kemoterapötiklere direnç gelişmesi nedeniyle prostat kanserini tedavi etmek için yeni ilaçlara ihtiyaç vardır. Fenformin biguanid grubu antidiyabetik bir ilaçtır ve antikanserojen etkileri de vardır. Fibroblast büyüme faktörü reseptörü 2 FGFR2, hücre proliferasyonunu ve farklılaşmasını destekleyen bir membran reseptörüdür. Çalışmamızda; PC-3 insan prostat kanseri hücrelerinde fenforminin FGFR2 üzerinden etkilerinin araştırılması amaçlandı. Deney grupları; kontrol grubu, 1 mM, 2 mM, 5 mM ve 10 mM fenformin uygulanan gruplar idi. Fenformin uygulamalarından 24 saat sonra WST-1 hücre canlılığı analizi yapıldı, ayrıca FGFR2 için immunositokimyasal boyamadan sonra H-Skoru hesaplandı. İstatistiksel analizler için SPSS programı kullanıldı. WST-1 analizi sonuçlarına göre; kontrol grubu ile 5 mM fenformin grubu, kontrol grubu ile 10 mM fenformin grubu ve 1 mM fenformin grubu ile 10 mM fenformin grubu karşılaştırıldığında hücre canlılığında istatistiksel olarak anlamlı derecede azalma tespit edildi p0.05, hepsi için. H-Skoru sonuçlarına göre; kontrol grubu ve 5 mM fenformin grubu, kontrol grubu ile 10 mM fenformin grubu, 1 mM fenformin grubu ile 5 mM fenformin grubu ve 1 mM fenformin grubu ile 10 mM fenformin grubu arasındaki FGFR2 ekspresyonunun azalması istatistiksel olarak anlamlıydı p0.05, hepsi için. Çalışmamızda fenformin, doza bağlı olarak PC-3 insan prostat kanseri hücreleri üzerinde FGFR2 ekspresyonunu azaltıcı ve hücre proliferasyonunu inhibe edici etkiler göstermiştir. En etkili dozun 10 mM fenformin olduğu tespit edilmiştir.

Makale detayları

Effects of Fenformin On Cell Viability and FGFR2 Expression in PC-3 Human Prostate Cancer Cell Line

Yazarlar:

Dilan Çetinavcı | Melike Özgül Önal | Gürkan Yiğittürk | Hülya Elbe | Feral Öztürk

Yayıncı:

Mugla Sitki Kocman University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.10 Issue 2, pp.84-89

Belge Tipi:

Makale

Yayın Tarihi:

8/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001296749

pISSN:

2148-8118

Phenformin

FGFR2

PC-3

Prostate CancerFenformin

FGFR2

PC-3

Prostat Kanseri

Sayı

Makale detayları

Yazarlar: Dilan Çetinavcı | Melike Özgül Önal | Gürkan Yiğittürk | Hülya Elbe | Feral Öztürk

Yayıncı: Mugla Sitki Kocman University

Ana Başlıklar: Klinik Tıp Bilimleri

Dergi: Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.10 Issue 2, pp.84-89

Belge Tipi: Makale

Yayın Tarihi: 8/2023

Belge Dili: Türkçe

Document ID (Org No.): 2001296749

pISSN: 2148-8118

Sayı

Yazarlar:

Dilan Çetinavcı | Melike Özgül Önal | Gürkan Yiğittürk | Hülya Elbe | Feral Öztürk

Yayıncı:

Mugla Sitki Kocman University

Ana Başlıklar:

Klinik Tıp Bilimleri

Dergi:

Muğla Sıtkı Koçman Üniversitesi Tıp Dergisi Vol.10 Issue 2, pp.84-89

Belge Tipi:

Makale

Yayın Tarihi:

8/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001296749

pISSN:

2148-8118